Cytosorbents (CTSO) Revenue (2011 - 2026)

Cytosorbents (CTSO) has reported Revenue for 16 consecutive years, with $9.6 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Revenue changed 0.17% year-over-year to $9.6 million; the trailing twelve-month figure through Jun 2026 stood at $37.2 million (up 3.07% YoY), and the FY2025 full-year result was $37.1 million, up 4.12% from the prior year.
• Revenue improved to $9.6 million in Q2 2026 per CTSO's latest filing, from $8.9 million in the prior quarter.
• Across five years, Revenue topped out at $9.6 million in Q2 2026 and bottomed at $8.1 million in Q3 2022.
• Historically, Revenue has averaged $9.0 million across 5 years, with a median of $8.9 million in 2024.
• The sharpest annual moves came in 2022 and 2023: Revenue retreated 29.35% in 2022, then rose 10.89% in 2023.
• Over 5 years, Revenue stood at $9.4 million in 2022, then retreated by 7.69% to $8.7 million in 2023, then gained by 5.57% to $9.2 million in 2024, then increased by 0.91% to $9.2 million in 2025, then rose by 4.32% to $9.6 million in 2026.
• According to Business Quant data, Revenue over the past three periods registered $9.6 million, $8.9 million, and $9.2 million for Q2 2026, Q1 2026, and Q4 2025 respectively.